82 related articles for article (PubMed ID: 36643868)
1. Derivation of human primary prostate epithelial cell lines by differentially targeting the
Wasserman JS; Fowle H; Hashmi R; Atar D; Patel K; Yarmahmoodi A; Macfarlane AW; Tan Y; Cukierman E; Gligorijevic B; Karami A; Whelan KA; Campbell KS; Graña X
Res Sq; 2024 May; ():. PubMed ID: 38766032
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.
Mahal BA; Gerke T; Awasthi S; Soule HR; Simons JW; Miyahira A; Halabi S; George D; Platz EA; Mucci L; Yamoah K
Eur Urol Oncol; 2022 Feb; 5(1):18-29. PubMed ID: 34446369
[TBL] [Abstract][Full Text] [Related]
3. Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient.
Valentine H; Aiken W; Morrison B; Zhao Z; Fowle H; Wasserman JS; Thompson E; Chin W; Young M; Clarke S; Gibbs D; Harrison S; McLaughlin W; Kwok T; Jin F; Campbell KS; Horvath A; Thompson R; Lee NH; Zhou Y; Graña X; Ragin C; Badal S
Cancer Res Commun; 2022 Nov; 2(11):1355-1371. PubMed ID: 36643868
[TBL] [Abstract][Full Text] [Related]
4. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
[TBL] [Abstract][Full Text] [Related]
5. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
6. Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells.
Teslow EA; Bao B; Dyson G; Legendre C; Mitrea C; Sakr W; Carpten JD; Powell I; Bollig-Fischer A
Mol Oncol; 2018 Jun; 12(7):1138-1152. PubMed ID: 29741809
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of human prostate carcinoma cell lines.
van Bokhoven A; Varella-Garcia M; Korch C; Johannes WU; Smith EE; Miller HL; Nordeen SK; Miller GJ; Lucia MS
Prostate; 2003 Nov; 57(3):205-25. PubMed ID: 14518029
[TBL] [Abstract][Full Text] [Related]
9. Immortalization of human primary prostate epithelial cells via CRISPR inactivation of the CDKN2A locus and expression of telomerase.
Zhao Z; Fowle H; Valentine H; Liu Z; Tan Y; Pei J; Badal S; Testa JR; Graña X
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):233-243. PubMed ID: 32873916
[TBL] [Abstract][Full Text] [Related]
10. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
11. Is It Time to Start Transitioning From 2D to 3D Cell Culture?
Jensen C; Teng Y
Front Mol Biosci; 2020; 7():33. PubMed ID: 32211418
[TBL] [Abstract][Full Text] [Related]
12. Organ-on-a-chip: recent breakthroughs and future prospects.
Wu Q; Liu J; Wang X; Feng L; Wu J; Zhu X; Wen W; Gong X
Biomed Eng Online; 2020 Feb; 19(1):9. PubMed ID: 32050989
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo.
Zhupanyn P; Ewe A; Büch T; Malek A; Rademacher P; Müller C; Reinert A; Jaimes Y; Aigner A
J Control Release; 2020 Mar; 319():63-76. PubMed ID: 31866504
[TBL] [Abstract][Full Text] [Related]
14. PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers centrosome destabilization.
Zhao Z; Kurimchak A; Nikonova AS; Feiser F; Wasserman JS; Fowle H; Varughese T; Connors M; Johnson K; Makhov P; Lindskog C; Kolenko VM; Golemis EA; Duncan JS; Graña X
Oncogenesis; 2019 Dec; 8(12):72. PubMed ID: 31822657
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
